RBC Capital analyst Kennen MacKay maintained a Hold rating on Amgen Inc (NASDAQ: AMGN) today and set a price target of $193. The company’s shares opened today at $207.29, close to its 52-week high of $210.19.
According to TipRanks.com, MacKay is a 5-star analyst with an average return of 19.7% and a 61.8% success rate. MacKay covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Akebia Therapeutics, and Puma Biotechnology.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amgen Inc with a $205.10 average price target, a -1.1% downside from current levels. In a report issued on September 17, Leerink Partners also maintained a Hold rating on the stock with a $209 price target.
Based on Amgen Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $6.08 billion and net profit of $2.3 billion. In comparison, last year the company earned revenue of $5.78 billion and had a net profit of $2.15 billion.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.